Detalhe da pesquisa
1.
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Future Oncol
; 18(29): 3245-3254, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950603
2.
Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats.
Int J Med Sci
; 19(11): 1628-1630, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36237984
3.
What Exactly Is Inflammation (and What Is It Not?).
Int J Mol Sci
; 23(23)2022 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36499232
4.
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
Future Oncol
; 15(30): 3427-3433, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31509028
5.
TGF-ß: the apex predator of immune checkpoints.
Future Oncol
; 19(30): 2013-2015, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37503560
6.
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Cancer Gene Ther
; 31(4): 517-526, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146006
7.
Patent and Marketing Exclusivities 101 for Drug Developers.
Recent Pat Biotechnol
; 17(3): 257-270, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635930
8.
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist.
Front Oncol
; 13: 1204143, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37313460
9.
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.
Front Oncol
; 13: 1176448, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37342189
10.
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME).
Front Immunol
; 14: 1104753, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36960054
11.
Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient.
Case Rep Oncol
; 16(1): 172-176, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37008834
12.
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.
Clin Colorectal Cancer
; 22(1): 92-99, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36529613
13.
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.
Drugs
; 83(5): 389-402, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920652
14.
Data Management 101 for drug developers: A peek behind the curtain.
Clin Transl Sci
; 16(9): 1497-1509, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37382299
15.
PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy.
Int J Radiat Oncol Biol Phys
; 116(3): 551-559, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36646388
16.
RRx-001 and the "Right stuff": Protection and treatment in outer space.
Life Sci Space Res (Amst)
; 35: 69-75, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36336372
17.
The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts.
Am J Cancer Res
; 12(4): 1912-1918, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35530283
18.
Nucleocapsid as a next-generation COVID-19 vaccine candidate.
Int J Infect Dis
; 122: 529-530, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788417
19.
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot.
Cancers (Basel)
; 14(19)2022 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36230621
20.
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC).
J Cancer
; 13(9): 2945-2953, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35912017